Domain's commitment to improving healthcare goes beyond delivering innovative medicines and devices to the market. We are also dedicated to improving treatment and diagnosis paradigms. The promise of molecular diagnostics is to develop highly accurate, precise and reproducible tests that lead to earlier detection of disease, optimized and personalized treatment for patients, and efficient allocation of healthcare expenditures.

Molecular Diagnostics

Domain has significantly increased investment into this sector over the past year. We believe genomic analysis techniques have reached a stage of maturity that will provide the foundation for fundamental changes in the practice of medicine and result in improved care and reduced costs.

Domain’s recent investments in molecular diagnostic companies include:

Domain will host its first Symposium of Molecular Diagnostic Leaders, a two-day gathering designed to bring together leaders of this important industry.

Click here to sign up to receive updates about this event.